To address whether core p53-effector lncRNAs mediate tumor-suppressive activities of p53 across cancers, we developed an approach that integrated lncRNA-mRNA networks and CRISPR and/or short hairpin (sh)/siRNA-mediated genome-scale loss-of-function screens across 382 cancer cell lines of the same 10 cancer types (refs. 41–43; Fig. 1; Supplementary Table S3). The gene discussed is TP53; the disease is cancer.